Compare DY & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DY | CYTK |
|---|---|---|
| Founded | 1969 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 10.7B |
| IPO Year | 1995 | 2004 |
| Metric | DY | CYTK |
|---|---|---|
| Price | $308.47 | $78.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 19 |
| Target Price | ★ $425.30 | $89.26 |
| AVG Volume (30 Days) | 583.3K | ★ 1.8M |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.71 | N/A |
| EPS | ★ 3.00 | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $30.96 | $7.37 |
| Revenue Next Year | $9.49 | $310.19 |
| P/E Ratio | $103.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $242.55 | $35.22 |
| 52 Week High | $566.47 | $88.31 |
| Indicator | DY | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 25.15 | 52.70 |
| Support Level | N/A | $78.27 |
| Resistance Level | $362.68 | $79.66 |
| Average True Range (ATR) | 16.81 | 2.11 |
| MACD | -9.75 | 0.37 |
| Stochastic Oscillator | 5.57 | 86.27 |
Dycom Industries Inc is a provider of specialty contracting services to the telecommunications infrastructure and utility industries throughout the United States. The company has two reporting segments: Communications and Building Systems. The Communications segment provides specialty contracting services, including program management, planning; engineering and design; aerial, underground, and wireless construction; maintenance; and fulfillment services for telecommunications and digital infrastructure providers. The Building Systems segment specializes in providing comprehensive building infrastructure solutions, including electrical, energy management, security, and fire safety systems for data centers and other critical facilities. The firm generates key revenue from Communications.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.